The intoxicating-hemp crackdown has added another layer of uncertainty for some publicly traded cannabis companies – most of which are still struggling to find a sustainable economic footing.

Curaleaf Holdings appears especially vulnerable as the federal ban on intoxicating hemp-derived THC products looms. The company had leaned on hemp-THC vapes, edibles and low-dose drinks as a diversification strategy, and the loss of that channel compounds existing pressure from oversupply and soft consumer demand.

New York-based Curaleaf started in hemp-derived THC by launching a product line in mid-2024 through its direct-to-consumer e-commerce platform and “Hemp Company” brand, and in a June 2024 press release the company explicitly pitched this move as a strategic expansion into a “rapidly growing” market.

Growth path is blocked

The messaging made clear that Curaleaf viewed hemp-THC products as a meaningful growth avenue, not a sideline. Yet the company has never disclosed how much revenue these products actually generate. It only says its hemp business reduces the company’s overall profitability, but provides no sales details — leaving its exposure to the federal ban unclear.

Curaleaf’s recent financials show the company’s general strain: through the first three quarters of 2025, the company generated more than US$900 million in revenue but still posted substantial net losses. It produced positive operating cash flow but remained unprofitable, underlining how even the largest multistate operators have struggled to turn scale into earnings.

Read more at Hemp Today.